Teva: The Market Is Pricing The Past, Not The Pipeline - Initiating Buy

Teva Pharmaceuticals is undergoing a strategic shift from generics to specialty branded medicines, complex generics, biosimilars, and innovation-led pipeline expansion. TEVA's key growth drivers include Austedo, Ajovy, Uzedy, and especially the late-stage immunology asset Duvakitug, which has shown compelling phase 2b efficacy and durability. Phase 2b data for Duvakitug in ulcerative colitis and Crohn's disease demonstrate robust remission rates and favorable safety, with multiple phase 3 trials underway.